Skip to main content

GOLDMAN SACHS GROUP INC

Position in KALV — KalVista Pharmaceuticals, Inc.

CIK 886982 NEW YORK, NY

Position in KALV

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$16,593,017
+$3,102,859 QoQ
Shares Held
824,293
-1.3% QoQ
Ownership
1.55%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#24
of 182 holders
Holding Since
Jun 2020
23 quarters on record
Voting authority Sole 99.98240916761394.ToString("F0")% Shared 0.ToString("F0")% None 0.0175908323860569.ToString("F0")%

Common Shares in KALV Over Time

Shares Held

Position Value (USD)

Derivatives in KALV

reported options exposure · as of Dec 31, 2023
CallValue
$2,984,100
CallShares
243,600
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

GOLDMAN SACHS GROUP INC holds $10,294,260,512 across 365 Biotechnology names. KALV ranks #114 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in KALV

Export CSV
24 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $16,593,017 824,293
2025-12-31 $13,490,158 835,304
2025-09-30 $21,926,203 1,800,181
2025-06-30 $1,519,369 134,398
2025-03-31 $3,922,860 339,936
2024-12-31 $2,775,390 327,673
2024-09-30 $1,552,193 134,041
2024-06-30 $2,507,820 212,888
2024-03-31 $709,595 59,831
2023-12-31 $1,066,962 87,099
2023-12-31 $2,984,100 243,600
2023-09-30 $2,010,858 208,812
2023-06-30 $2,639,799 293,311
2023-03-31 $2,165,304 275,484
2022-12-31 $2,336,964 345,705
2022-09-30 $4,906,991 338,180
2022-06-30 $2,964,545 301,275
2022-03-31 $2,457,231 166,705
2021-12-31 $1,315,471 99,431
2021-09-30 $1,209,197 69,295
2021-06-30 $757,375 31,610
2021-03-31 $1,402,648 54,599
2020-12-31 $200,724 10,570
2020-06-30 $445,050 36,781